PureTech Health (NASDAQ:PRTC) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines that harness the body’s immune, nervous and other biological systems. Founded in 2015 and headquartered in Boston, Massachusetts, with additional offices in London and Cambridge, the company pursues a platform-based approach to drug development. This model leverages deep scientific research, translational biology and human genetics to create novel therapies across immunology, oncology, neuroscience and metabolic disorders.
Central to PureTech’s strategy is the incubation and funding of a diversified portfolio of clinical and preclinical stage programs. Through its wholly owned and partnered subsidiaries, the company advances candidates targeting conditions such as inflammatory bowel disease, fibrotic diseases, Alzheimer’s disease and obesity. Notable programs include a proprietary gut microbiome–derived therapy for chronic gastrointestinal disorders and an engineered T-cell platform for solid tumors. By combining in-house expertise with external collaborations, PureTech aims to accelerate the translation of early discoveries into patient-ready treatments.
PureTech’s research and development activities are supported by multidisciplinary teams situated across North America and Europe. The company maintains strategic partnerships with leading academic institutions, biotech firms and contract research organizations to expand its scientific capabilities and streamline clinical execution. This global footprint enables PureTech to conduct multi-center trials and engage regulatory authorities in the U.S., U.K., European Union and beyond, positioning its programs for seamless progression through clinical milestones.
The company is led by a management team with deep industry experience in drug discovery, development and commercialization. Chief Executive Officer Daphne Zohar, a seasoned biotech entrepreneur, oversees corporate strategy and investor relations, while Chief Scientific Officer Dr. Kathleen Lewis guides the scientific agenda. Under their leadership, PureTech has successfully spun out multiple affiliated entities and retains minority equity stakes in programs that have attracted significant follow-on investment. With a capital-efficient structure and a long-term vision, the company remains committed to advancing breakthrough therapies for underserved patient populations.
AI Generated. May Contain Errors.
